These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30022113)

  • 1. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.
    Lichtenstein GR; Feagan BG; Mahadevan U; Salzberg BA; Langholff W; Morgan JG; Safdi M; Nissinen R; Taillard F; Sandborn WJ; Cohen RD
    Am J Gastroenterol; 2018 Nov; 113(11):1678-1688. PubMed ID: 30022113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure to Infliximab During Pregnancy: Post-Marketing Experience.
    Geldhof A; Slater J; Clark M; Chandran U; Coppola D
    Drug Saf; 2020 Feb; 43(2):147-161. PubMed ID: 31677004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.
    Mahadevan U; Kane S; Sandborn WJ; Cohen RD; Hanson K; Terdiman JP; Binion DG
    Aliment Pharmacol Ther; 2005 Mar; 21(6):733-8. PubMed ID: 15771759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.
    de Lima A; Zelinkova Z; van der Ent C; Steegers EA; van der Woude CJ
    Gut; 2016 Aug; 65(8):1261-8. PubMed ID: 25966992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
    Chugh R; Long MD; Jiang Y; Weaver KN; Beaulieu DB; Scherl EJ; Mahadevan U
    Am J Gastroenterol; 2024 Mar; 119(3):468-476. PubMed ID: 37796648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
    Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
    Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
    Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
    Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kimball AB; Guenther L; Kalia S; de Jong EMGJ; Lafferty KP; Chen DY; Langholff W; Shear NH
    JAMA Dermatol; 2021 Mar; 157(3):301-306. PubMed ID: 33533924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
    Schnitzler F; Fidder H; Ferrante M; Ballet V; Noman M; Van Assche G; Spitz B; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Inflamm Bowel Dis; 2011 Sep; 17(9):1846-54. PubMed ID: 21830263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G; Vermeire S; Lambrecht G; Baert F; Bossuyt P; Pariente B; Buisson A; Bouhnik Y; Filippi J; Vander Woude J; Van Hootegem P; Moreau J; Louis E; Franchimont D; De Vos M; Mana F; Peyrin-Biroulet L; Brixi H; Allez M; Caenepeel P; Aubourg A; Oldenburg B; Pierik M; Gils A; Chevret S; Laharie D;
    Gastroenterology; 2018 Apr; 154(5):1343-1351.e1. PubMed ID: 29317275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
    Katz JA; Antoni C; Keenan GF; Smith DE; Jacobs SJ; Lichtenstein GR
    Am J Gastroenterol; 2004 Dec; 99(12):2385-92. PubMed ID: 15571587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
    Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Langholff W; Londhe A; Sandborn WJ
    Am J Gastroenterol; 2014 Feb; 109(2):212-23. PubMed ID: 24394749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception.
    Angelucci E; Cocco A; Viscido A; Caprilli R
    Inflamm Bowel Dis; 2008 Mar; 14(3):435-6. PubMed ID: 18050300
    [No Abstract]   [Full Text] [Related]  

  • 16. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.
    Mahadevan U; Long MD; Kane SV; Roy A; Dubinsky MC; Sands BE; Cohen RD; Chambers CD; Sandborn WJ;
    Gastroenterology; 2021 Mar; 160(4):1131-1139. PubMed ID: 33227283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
    Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
    Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
    Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
    World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.